Clinical Trial Update: Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa [Phase 1]

View source ↗

Summary

Phase 1 study evaluating VXCO-100, a SARS-CoV candidate vaccine, in adults in South Africa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars

Drugs mentioned

• VXCO-100

Snippet

Sponsor: Vaccine Company, Inc. | Conditions: SARS-CoV, SARS-CoV-2 | Phase 1 | Status: COMPLETED